Asif Ali sold $8.3M of PTGX
Chief Financial Officer at Protagonist Therapeutics, Inc. 58,629 shares at an average of $141.78, traded Sep 30, 2026, filed Oct 2, 2026.
Score components
- +22RoleCFO
- +25Trade size$8.3M at market
- +10Share of holdings soldSold 50% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-113279, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +9,229 | $38.98 | $360k | 68,232 | 10 d ago |
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +28,438 | $23.42 | $666k | 96,670 | 10 d ago |
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +15,650 | $19.19 | $300k | 112,320 | 10 d ago |
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +5,312 | $12.17 | $65k | 117,632 | 10 d ago |
| Sep 30, 2026 | SOpen-market sale Common Stock10b5-1 | -12,595 | $141.77 | $1.8M | 105,037 | 10 d ago |
| Sep 30, 2026 | SOpen-market sale Common Stock10b5-1 | -46,034 | $141.78 | $6.5M | 59,003 | 10 d ago |
| Sep 30, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -9,229 | $0.00 | $0 | 29,291 | 10 d ago |
| Sep 30, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -28,438 | $0.00 | $0 | 49,562 | 10 d ago |
| Sep 30, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,650 | $0.00 | $0 | 51,150 | 10 d ago |
| Sep 30, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,312 | $0.00 | $0 | 25,235 | 10 d ago |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 42Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% | |
| 42Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $3.8M 46,203 shares | -43% | |
| 43Moderate | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $708k 8,588 shares | -10% | |
| 28Weak | PTGXsell Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $230k 2,712 shares | -3% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $979k 12,000 shares | -70% | |
| 18Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $257k 4,000 shares | -44% | |
| 18Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $237k 4,000 shares | -30% | |
| 44Moderate | PTGXsell Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $571k 10,415 shares | -2% | |
| 50Moderate | PTGXsell Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $2.9M 52,444 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.